Crescendo Bioscience has raised $31 million in series C equity financing. The molecular diagnostics company has also entered a strategic investment agreement with Myriad Genetics for $25 million, raising a total of $56 million

The investment round was led by Aeris Capital. Existing investors Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers and others also took part in the round. Crescendo develops quantitative biomarker tests for rheumatoid arthritis and other inflammatory diseases.

Click here for the release from Crescendo Bioscience.